Evaluation of Long-Term Safety of Pirfenidone (Esbriet) in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Inclusion Criteria: * A clinical decision has been made, prior to study enrolment, to prescribe Esbriet * Participants who are newly prescribed Esbriet therapy * Initiation of Esbriet therapy is not more than 30 days prior to study enrolment Exclusion Criteria: * Participants receiving an investigational agent defined as any drug that has not been approved for marketing for any indication in the country of the participating site * Participant has received Esbriet therapy 30 days or more prior to current treatment course (e.g., prior participation in clinical trials) * Participant has any contraindication for the use of Esbriet, according to the current local version of the Summary of Product Characteristics (SPC)